超声(IOTA-ADNEX)与磁共振成像(ADNEX MR)在高危患者中诊断卵巢癌的比较:一项前瞻性研究
前瞻性单中心诊断准确性研究,纳入342例一线超声怀疑附件恶性肿瘤患者,比较IOTA-ADNEX模型与ADNEX MR评分系统作为二线影像的鉴别良恶性能力;IOTA-ADNEX的AUC为0.96(95%CI 0.94–0.98),ADNEX MR为0.93(95%CI 0.91–0.96),两者诊断准确性相当,可按中心资源选择用于二线评估。
要点
- IOTA-ADNEX模型鉴别附件良恶性肿瘤的AUC为0.96,ADNEX MR为0.93。
- 两种方法在不同病变形态或大小分层下表现相似。
- IOTA-ADNEX区分交界性与I期浸润癌时AUC降至0.71。
核心结论
- IOTA-ADNEX模型与ADNEX MR评分系统在本研究中鉴别附件良恶性肿瘤的诊断准确性相当,按病变形态分层结果似乎一致,两者均可用于一线超声提示恶性风险肿块的二线评估,取决于特定中心的资源。
研究设计与样本
- 前瞻性单中心诊断准确性研究,设计为头对头比较,纳入2021年5月至2022年12月丹麦奥胡斯大学医院因一线影像怀疑附件恶性转诊的患者,共342例患者(分析342个病变)。
- 所有患者接受系统性专家超声检查(含IOTA-ADNEX风险估计)和系统性MRI扫描(由专家放射科医师分配ADNEX MR评分),超声检查者与放射科医师对其他影像结果和参考标准(肿瘤结局)设盲。
- 参考标准为原发附件肿块的病理组织学诊断,少数病例为临床随访;交界性肿瘤、浸润性附件恶性肿瘤和附件转移归为恶性肿瘤。
主要发现
- 队列中78.1%患者为绝经后,恶性肿瘤总患病率为58.8%。
- IOTA-ADNEX模型(含或不含CA 125)区分良恶性肿瘤的AUC为0.96(95%CI 0.94–0.98),ADNEX MR的AUC为0.93(95%CI 0.91–0.96)。
- 超声与MRI对关键形态学特征的一致性为中等至相当(κ=0.46–0.75),对病变大小测量的一致性为好至优(ICC=0.78–0.92)。
- IOTA-ADNEX模型与ADNEX MR评分系统在不同病变形态或大小下表现相似;IOTA-ADNEX模型校准良好,对肿瘤亚型的多项判别能力总体较高,但区分交界性肿瘤与I期浸润性恶性肿瘤时AUC为0.71(95%CI 0.56–0.82)。
关键数值与推荐
- IOTA-ADNEX模型鉴别良恶性肿瘤的AUC为0.96(95%CI 0.94–0.98),ADNEX MR为0.93(95%CI 0.91–0.96)。
- IOTA-ADNEX模型区分交界性肿瘤与I期浸润性恶性肿瘤的AUC为0.71(95%CI 0.56–0.82)。
临床怎么用
- 作者认为,IOTA-ADNEX模型和ADNEX MR评分系统均可用于一线超声检查中 deemed at risk of malignancy 肿块的二线评估,取决于特定中心的资源。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Objectives To systematically validate and compare ultrasonography, using the ultrasound-based International Ovarian Tumor Analysis – Assessment of Different NEoplasias in the adneXa (IOTA-ADNEX) model, with magnetic resonance imaging (MRI), using the MRI-based ADNEX MR scoring system, as second-line imaging modalities for estimating the risk of adnexal malignancy in patients identified as being at risk of malignancy on first-line ultrasound examination. Methods This was a prospective, single-center diagnostic accuracy study designed as a head-to-head comparison. All patients referred to a tertiary referral center at Aarhus University Hospital, Aarhus, Denmark, for suspected adnexal malignancy on first-line imaging between May 2021 and December 2022 were offered second-line diagnostic testing. This comprised both a systematic expert ultrasound examination, including IOTA-ADNEX risk estimation, and a systematic MRI scan with ADNEX MR scores assigned by expert radiologists. The imaging assessments were performed prospectively, with ultrasound examiners and radiologists blinded to the results of other imaging modalities and to the reference standard (tumor outcome). The reference standard was a histopathological diagnosis of the primary adnexal mass or, in a small number of cases, clinical follow-up. Borderline tumors, invasive adnexal malignancy and metastases to the adnexa were grouped as malignancies. Diagnostic performance of the IOTA-ADNEX model, ADNEX MR scoring system and CA 125 for predicting malignancy was evaluated using the area under the receiver-operating-characteristics curve (AUC), and AUCs were compared using DeLong's test. Diagnostic metrics were estimated at clinically relevant cut-offs and scores. Agreement between modalities was assessed for the identification of morphological features and overall risk estimation using Cohen's kappa statistics, intraclass correlation coefficients (ICC) and Bland–Altman plots. For the IOTA-ADNEX model, calibration and the ability to discriminate between tumor subtypes were evaluated. Results The included cohort comprised 342 patients (342 lesions analyzed). In the final cohort, 78.1% of patients were postmenopausal and the overall prevalence of malignancy was 58.8%. The AUC for distinguishing patients with benign tumors from those with malignant tumors was 0.96 (95% CI, 0.94–0.98) for the IOTA-ADNEX model (with or without CA 125) compared with an AUC of 0.93 (95% CI, 0.91–0.96) for ADNEX MR. Agreement between ultrasound and MRI ranged from moderate to substantial for key morphological features (κ = 0.46-0.75) and from good to excellent for lesion-size measurements (ICC = 0.78-0.92). The IOTA-ADNEX model performed similarly to the ADNEX MR scoring system regardless of lesion morphology or size. The IOTA-ADNEX model had good calibration. Furthermore, its multinomial discriminative ability between tumor subtypes was generally high, although performance was reduced when distinguishing borderline tumors from Stage-I invasive malignancy (AUC, 0.71 (95% CI, 0.56-0.82)). Conclusions The IOTA-ADNEX model and ADNEX MR scoring system demonstrated comparable diagnostic accuracy for differentiating benign from malignant adnexal masses in this study. Results appeared to be consistent when stratified by lesion morphology. Both modalities may be used for second-line assessment of masses deemed at risk of malignancy in the first-line ultrasound examination, depending on resources in specific centers. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Ultrasound in Obstetrics and Gynecology:Ultrasonography (IOTA‐ADNEX) vs magnetic resonance imaging (ADNEX MR) for diagnosing ovarian cancer in high‐risk patients: a prospective study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。